Description: Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Home Page: www.advaxis.com
9 Deer Park Drive
Monmouth Junction,
NJ
08852
United States
Phone:
609 452 9813
Officers
| Name | Title |
|---|---|
| Mr. Kenneth A. Berlin J.D. | Pres & CEO |
| Mr. Igor Gitelman CPA, CPA, M.B.A., MBA | Chief Accounting Officer, Interim CFO & VP of Fin. |
| Dr. Andres A. Gutierrez M.D., Ph.D. | Exec. VP & Chief Medical Officer |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1295 |
| Price-to-Sales TTM: | 14.7455 |
| IPO Date: | 2005-07-28 |
| Fiscal Year End: | October |
| Full Time Employees: | 14 |